Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
Randi
Maria Luigia
ML
Ruzzon
Elisabetta
E
Luzzatto
Guido
G
Tezza
Fabiana
F
Girolami
Antonio
A
Fabris
Fabrizio
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002066:Busulfan / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000494:pharmacology*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy; D011087:Polycythemia Vera / Q000188:drug therapy*; D012189:Retrospective Studies; D013922:Thrombocytosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D002066:Busulfan; D006918:Hydroxyurea